Polycythemia Vera - Pipeline Disease Research Report 2020 – Bharat Book Bureau


Posted October 16, 2020 by Vidhyanigam98

Polycythemia vera (PV) may not cause signs or symptoms for years.

 
Bharat Book Bureau Provides the Treding Market Research Report on "Polycythemia Vera - Pipeline Insight, 2020" under Life Sciences Category. The report offers a collection of superior market researach, market analysis, competitive intelligence and Market reports.

“Polycythemia vera – Pipeline Insight, 2020,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Polycythemia vera pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered

• Global coverage
Polycythemia vera Understanding
Polycythemia vera: Overview
Polycythemia vera, or PV, is a rare blood disease in which body makes too many red blood cells. The extra red blood cells make the blood thicker than normal. As a result, blood clots can form more easily. These clots can block blood flow through arteries and veins, which can cause a heart attack or stroke. Thicker blood also doesn't flow as quickly to body as normal blood. Slowed blood flow prevents organs from getting enough oxygen, which can cause serious problems, such as angina.

Request a Free Sample Copy Polycythemia Vera - Pipeline Disease Report@
https://www.bharatbook.com/marketreports/sample/reports/2187329


Symptoms
The signs and symptoms of PV include:
• Headaches, dizziness, and weakness
• Shortness of breath and problems breathing while lying down
• Feelings of pressure or fullness on the left side of the abdomen due to an enlarged spleen (an organ in the abdomen)
• Double or blurred vision and blind spots
• Itching all over (especially after a warm bath), reddened face, and a burning feeling on your skin (especially your hands and feet)
• Bleeding from your gums and heavy bleeding from small cuts
• Unexplained weight loss
• Fatigue (tiredness)
• Excessive sweating
• Very painful swelling in a single joint, usually the big toe (called gouty arthritis)

Diagnosis
Polycythemia vera (PV) may not cause signs or symptoms for years. The disease often is found during routine blood tests done for other reasons. If the results of the blood tests aren't normal, the doctor may want to do more tests. The doctor will diagnose PV based on signs and symptoms, age and overall health, medical history, a physical exam, and test results of the patients. During the physical exam, the doctor will look for signs of PV. He or she will check for an enlarged spleen, red skin on your face, and bleeding from gums. Once it is confirmed that the patient have polycythemia, the next step is to find out whether they have primary polycythemia (polycythemia vera) or secondary polycythemia.

The medical history and physical exam may confirm which type of polycythemia you have. If not, the patient may have tests that check the level of the hormone erythropoietin (EPO) in blood.
People who have PV have very low levels of EPO. People who have secondary polycythemia usually have normal or high levels of EPO.

Treatment
The goals of treating PV are to control symptoms and reduce the risk of complications, especially heart attack and stroke. To do this, PV treatments reduce the number of red blood cells and the level of hemoglobin (an iron-rich protein) in the blood. This brings the thickness of your blood closer to normal. Blood with normal thickness flows better through the blood vessels. This reduces the chance that blood clots will form and cause a heart attack or stroke. Blood with normal thickness also ensures that your body gets enough oxygen. This can help reduce some of the signs and symptoms of PV, such as headaches, vision problems, and itching.

Polycythemia vera Emerging Drugs Chapters
This segment of the Polycythemia vera report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Polycythemia Vera Emerging Drugs
• PTG-300: Protagonist Therapeutics
PTG-300 is a mimetic of the natural hormone hepcidin that is currently in a phase II study in polycythemia vera (PV), a rare blood disorder, and a phase II study in hereditary hemochromatosis (HH), a blood disorder arising from absence or deficiency of hepcidin gene. Hepcidin is a master regulator of iron homeostasis and controls the absorption, storage, and distribution of iron in the body.

Browse our full report with Table of content:
https://www.bharatbook.com/marketreports/polycythemia-vera-pipeline-insight-2020/2187329

About Bharat Book Bureau:
Bharat Book is Your One-Stop-Shop with an exhaustive coverage of 12,00,000 reports and insights that includes latest Market Study, Market Trends & Analysis, Forecasts, Customized Intelligence, Newsletters and Online Databases, Overall a comprehensive coverage of major industries with a further segmentation of 100+ subsectors.

Contact us at:
Bharat Book Bureau
Tel: +912227810772 / 27810773
Email: [email protected]
Website: www.bharatbook.com
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By Vidhya Nigam
Phone 02227810772
Business Address 808, Real Tech Park, 8th Floor, Sector - 30A, Vashi, Navi Mumbai - 400703, India.
30A, Vashi, Navi Mumbai - 400703, India.
Country India
Categories Science
Tags polycythemia vera pipeline disease , polycythemia vera pipeline disease research report , polycythemia vera pipeline disease report
Last Updated October 16, 2020